S'abonner

Staphylococcal serine protease–like proteins are pacemakers of allergic airway reactions to Staphylococcus aureus - 18/04/17

Doi : 10.1016/j.jaci.2016.03.045 
Sebastian Stentzel, PhD a, Andrea Teufelberger b, Maria Nordengrün a, Julia Kolata, PhD a, c, Frank Schmidt, PhD d, e, Koen van Crombruggen, PhD b, Stephan Michalik, PhD d, e, Jana Kumpfmüller, PhD f, k, Sebastian Tischer a, Thomas Schweder, PhD f, Michael Hecker, PhD g, Susanne Engelmann, PhD g, h, i, Uwe Völker, PhD d, Olga Krysko, PhD b, Claus Bachert, MD, PhD b, j, Barbara M. Bröker, MD a,
a Department of Immunology, University Medicine Greifswald, Greifswald, Germany 
d Interfaculty Institute for Genetics and Functional Genomics, Department of Functional Genomics, University Medicine Greifswald, Greifswald, Germany 
e Junior Group Applied Proteomics, ZIK FunGene, University Medicine Greifswald, Greifswald, Germany 
b Upper Airways Research Laboratory, Ghent University, Ghent, Belgium 
c Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands 
f Department of Pharmaceutical Biotechnology, Institute of Pharmacy, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany 
g Institute for Microbiology, Ernst-Moritz-Arndt-University Greifswald, Greifswald, Germany 
h Institute for Microbiology, University of Braunschweig, Braunschweig, Germany 
i Helmholtz Center for Infection Research, Microbial Proteomics, Braunschweig, Germany 
j Division of Ear, Nose, and Throat Diseases, Clintec, Karolinska Institute, Stockholm, Sweden 
k Department of Biomolecular Chemistry, Leibniz Institute for Natural Product Research and Infection Biology, HKI, Jena, Germany 

Corresponding author: Barbara M. Bröker, MD, Institut für Immunologie und Transfusionsmedizin, Universitätsmedizin Greifswald, Ferdinand-Sauerbruch-Straße, DZ7, 17475 Greifswald, Germany.Institut für Immunologie und TransfusionsmedizinUniversitätsmedizin GreifswaldFerdinand-Sauerbruch-Straße, DZ7Greifswald17475Germany

Abstract

Background

A substantial subgroup of asthmatic patients have “nonallergic” or idiopathic asthma, which often takes a severe course and is difficult to treat. The cause might be allergic reactions to the gram-positive pathogen Staphylococcus aureus, a frequent colonizer of the upper airways. However, the driving allergens of S aureus have remained elusive.

Objective

We sought to search for potentially allergenic S aureus proteins and characterize the immune response directed against them.

Methods

S aureus extracellular proteins targeted by human serum IgG4 were identified by means of immunoblotting to screen for potential bacterial allergens. Candidate antigens were expressed as recombinant proteins and used to analyze the established cellular and humoral immune responses in healthy adults and asthmatic patients. The ability to induce a type 2 immune response in vivo was tested in a mouse asthma model.

Results

We identified staphylococcal serine protease–like proteins (Spls) as dominant IgG4-binding S aureus proteins. SplA through SplF are extracellular proteases of unknown function expressed by S aureus in vivo. Spls elicited IgE antibody responses in most asthmatic patients. In healthy S aureus carriers and noncarriers, peripheral blood T cells elaborated TH2 cytokines after stimulation with Spls, as is typical for allergens. In contrast, TH1/TH17 cytokines, which dominated the response to S aureus α-hemolysin, were of low concentration or absent. In mice inhalation of SplD without adjuvant induced lung inflammation characterized by TH2 cytokines and eosinophil infiltration.

Conclusion

We identify Spls as triggering allergens released by S aureus, opening prospects for diagnosis and causal therapy of asthma.

Le texte complet de cet article est disponible en PDF.

Key words : Asthma, IgE, Staphylococcus aureus, serine protease-like proteins, type 2 inflammation

Abbreviations used : APC, BALF, FITC, Hla, OVA, PE, PerCP, SEB, Spl, TCM


Plan


 Supported by the Deutsche Forschungsgemeinschaft (CRC-TRR34, GRK 1870), the German Ministry of Education and Research (Program Infection Genomics, 0315829, 03Z1CN22), the Interuniversity Attraction Poles Program Belgian Science Policy (no. IAP P7/30 to C.B.) and by the Research Foundation Flanders (FWO to A.T.).
 Disclosure of potential conflict of interest: S. Stentzel receives research support from DFG. M. Nordengrün receives research support from DFG. F. Schmidt has research funding from BMBF (03Z1CN22). S. Engelmann receives travel support from BMBF. U. Völker receives research support from DFG. C. Bachert receives research support from Interuniversity Attraction Poles Program Belgian Science Policy (no. IAP P7/30) and has patents EP 13 169 686.6. B. M. Bröker receives research support from DFG, BMBF European Union; has a patent pending (EP 13 169 686.6 and EP 10 194 983.2), and received royalties from BD Bioscience. The rest of the authors declare that they have no relevant conflicts of interest.


© 2016  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 139 - N° 2

P. 492 - février 2017 Retour au numéro
Article précédent Article précédent
  • Factors influencing the infant gut microbiome at age 3-6 months: Findings from the ethnically diverse Vitamin D Antenatal Asthma Reduction Trial (VDAART)
  • Joanne E. Sordillo, Yanjiao Zhou, Michael J. McGeachie, John Ziniti, Nancy Lange, Nancy Laranjo, Jessica R. Savage, Vincent Carey, George O'Connor, Megan Sandel, Robert Strunk, Leonard Bacharier, Robert Zeiger, Scott T. Weiss, George Weinstock, Diane R. Gold, Augusto A. Litonjua
| Article suivant Article suivant
  • Early life rhinovirus wheezing, allergic sensitization, and asthma risk at adolescence
  • Frederick J. Rubner, Daniel J. Jackson, Michael D. Evans, Ronald E. Gangnon, Christopher J. Tisler, Tressa E. Pappas, James E. Gern, Robert F. Lemanske

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.